Abstract:Inactivation of the most important tumour suppressor gene TP53 occurs in most, if not all, human cancers. Loss of functional wild-type p53 is achieved via two main mechanisms: mutation of the gene leading to an absence of tumour suppressor activity and, in some cases, gain-of-oncogenic function; or inhibition of the wild-type p53 protein mediated by overexpression of its negative regulators MDM2 and MDMX. Because of its high potency as a tumour suppressor and the dependence of at least some established tumours on its inactivation, p53 appears to be a highly attractive target for the development of new anticancer drugs. However, p53 is a transcription factor and therefore has long been considered undruggable. Nevertheless, several innovative strategies have been pursued for targeting dysfunctional p53 for cancer treatment. In mutant p53-expressing tumours, the predominant strategy is to restore tumour suppressor function with compounds acting either in a generic manner or otherwise selective for one or a few specific p53 mutations. In addition, approaches to deplete mutant p53 or to target vulnerabilities created by mutant p53 expression are currently under development. In wild-type p53 tumours, the major approach is to protect p53 from the actions of MDM2 and MDMX by targeting these negative regulators with inhibitors. Although the results of at least some clinical trials of MDM2 inhibitors and mutant p53-restoring compounds are promising, none of the agents has yet been approved by the FDA. Alternative strategies, based on a better understanding of p53 biology, the mechanisms of action of compounds and treatment regimens as well as the development of new technologies are gaining interest, such as proteolysis-targeting chimeras for MDM2 degradation. Other approaches are taking advantage of the progress made in immune-based therapies for cancer. In this Review, we present these ongoing clinical trials and emerging approaches to re-evaluate the current state of knowledge of p53-based therapies for cancer.

TP53: the unluckiest of genes?

p53: 800 million years of evolution and 40 years of discovery

Mutant p53 as a guardian of the cancer cell

Mutant p53: it’s not all one and the same

TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review)

Putting p53 in Context

p53 signaling in cancer progression and therapy

Mutant p53 in Cancer Progression and Targeted Therapies

Mutant P53 in the formation and progression of the tumor microenvironment: Friend or foe

Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

Mutant p53 in cancer therapy-the barrier or the path.

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Functional Diversity of P53 in Human and Wild Animals

Modeling the Etiology of p53-mutated Cancer Cells

Tumor Suppressor P53 and Its Gain-of-function Mutants in Cancer

Abstract 2633: TP53 Loss Creates Therapeutic Vulnerability in Cancer

Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy

Mutant P53 in Cancer: Accumulation, Gain-of-Function, and Therapy.

Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant

Translating p53-based therapies for cancer into the clinic

Recent Advances on Mutant p53: Unveiling Novel Oncogenic Roles, Degradation Pathways, and Therapeutic Interventions